BMI View: With lower revenues from oil exports and significant costs associated with the battle against
Islamic State, the Iraqi government will continue to face headwinds in providing healthcare to its
population. Furthermore, economic headwinds will also feed through to consumer spending, deterring
investment in adequate access to healthcare and medicines, which in turn will weigh on a more significant
market recovery. However, strong demand for healthcare will continue to translate to pharmaceuticals and
healthcare sector growth over the forecast period.
Headline Expenditure Projections
? Pharmaceuticals: IQD2.02trn (USD1.71bn) in 2015 to IQD2.19trn (USD1.71bn) in 2016; +8.2% in
local currency and +0.2% in US dollar terms. Forecast broadly in line with last quarter.
? Healthcare: IQD11.77trn (USD9.96bn) in 2015 to IQD12.54trn (USD9.83bn) in 2016; +6.6% in local
currency and -1.3% in US dollar terms. Forecast revised downwards from last quarter.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Iraq 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iraq 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iraq 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iraq 2012-2020) 17
Pharmaceutical Trade Forecast 18
Table: Pharmaceutical Trade Data And Forecasts (Iraq 2014-2020) 20
Table: Pharmaceutical Trade Data And Forecasts local currency (Iraq 2014-2020) 20
Industry Risk/Reward Index 21
Middle East and Africa Risk/Reward Index - Q2 2016 21
Iraq Risk/Reward Index 28
Rewards 28
Risks 28
Regulatory Review 30
Regulatory Regime 30
Intellectual Property Issues 32
Pricing Regime 33
Reimbursement Regime 34
Market Overview 35
Healthcare Sector 35
Table: Healthcare Resources (Iraq 2010-2015) 37
Table: Healthcare Personnel (Iraq 2010-2015) 37
Table: Healthcare Activity (Iraq 2010-2015) 38
Research & Development 40
Clinical Trials 40
Epidemiology 41
Competitive Landscape 46
Research-Based Industry 46
Table: Multinational Market Activity 47
Generic Drugmakers 47
Pharmaceutical Distribution 48
Pharmaceutical Retail Sector 48
Company Profile 50
Samarra 50
Ninewa 52
Awamedica 54
Demographic Forecast 56
Table: Population Headline Indicators (Iraq 1990-2025) 57
Table: Key Population Ratios (Iraq 1990-2025) 57
Table: Urban/Rural Population & Life Expectancy (Iraq 1990-2025) 58
Table: Population By Age Group (Iraq 1990-2025) 58
Table: Population By Age Group % (Iraq 1990-2025) 59
Glossary 61
Methodology 63
Pharmaceutical Expenditure Forecast Model 63
Healthcare Expenditure Forecast Model 63
Notes On Methodology 64
Risk/Reward Index Methodology 65
Index Overview 66
Table: Pharmaceutical Risk/Reward Index Indicators 66
Indicator Weightings 67

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Iraq 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iraq 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iraq 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iraq 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Iraq 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Iraq 2014-2020)
Table: Healthcare Resources (Iraq 2010-2015)
Table: Healthcare Personnel (Iraq 2010-2015)
Table: Healthcare Activity (Iraq 2010-2015)
Table: Multinational Market Activity
Table: Population Headline Indicators (Iraq 1990-2025)
Table: Key Population Ratios (Iraq 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Iraq 1990-2025)
Table: Population By Age Group (Iraq 1990-2025)
Table: Population By Age Group % (Iraq 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators